Cargando…
Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases
BACKGROUND: Recent studies have suggested obesity could contribute to improved outcomes of immune checkpoint inhibitor (ICI)-based treatment. Non-alcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease, is also obesity-related, but its association with the efficacy of IC...
Autores principales: | Zhou, Juan, Zhou, Fei, Chu, Xiangling, Zhao, Jing, Wu, Yan, Zhao, Wencheng, Xu, Chuan, Su, Chunxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225134/ https://www.ncbi.nlm.nih.gov/pubmed/32420071 http://dx.doi.org/10.21037/tlcr.2020.04.15 |
Ejemplares similares
-
Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Li, Xing, et al.
Publicado: (2020) -
Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer
por: Zhou, Juan, et al.
Publicado: (2021) -
Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer
por: Yu, Xin, et al.
Publicado: (2021) -
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021) -
Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Xie, Mengqing, et al.
Publicado: (2021)